Functional androgen receptor confers sensitization of androgen-independent prostate cancer cells to anticancer therapy via caspase activation

Biochemical and Biophysical Research Communications

Volumn 309, Issue 4, 2003, Pages 937-945

  Davis, Rodney ^a   Jia, Dingwu ^a   Cinar, Bekir ^b   Sikka, Suresh C ^a   Moparty, Krishnarao ^a   Zhau, Haiyen E ^c   Chung, Leland W ^c   Agrawal, Krishna C ^a   Abdel Mageed, Asim B ^a  

^a TULANE UNIVERSITY HEALTH SCIENCES CENTER   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

^c EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Androgen receptor; Anticancer therapy; Apoptosis; Caspase; Sensitization

Indexed keywords

4 HYDROXYFLUTAMIDE; ANDROGEN RECEPTOR; CASPASE; DNA FRAGMENT; FLUTAMIDE; LIPOCORTIN 5; PACLITAXEL; UNCLASSIFIED DRUG;

ARTICLE; CANCER THERAPY; CARCINOMA CELL; CONTROLLED STUDY; CYTOTOXICITY; ENZYME ACTIVATION; ENZYME ACTIVITY; GAMMA IRRADIATION; HUMAN; HUMAN CELL; MOLECULAR DYNAMICS; PHENOTYPE; PRIORITY JOURNAL; PROSTATE CARCINOMA; PROTEIN EXPRESSION; SENSITIZATION;

EID: 0141453290     PISSN: 0006291X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bbrc.2003.08.096     Document Type: Article

References (51)

1. Boring C.C., Squires T.S., Tong T. Cancer statistics. CA Cancer J. Clin. 41:1991;19-36.
2. Epstein J.I., Pizov G., Walsh P.C. Correlation of pathologic findings with progression after radical retropubic prostatectomy. Cancer. 71:1993;3582-3593.
3. Isaacs J.T., Coffey D.S. Adaptation versus selection as the mechanism responsible for the relapse of prostatic cancer to androgen ablation therapy as studied in the Dunning R-3327-H adenocarcinoma. Cancer Res. 41:1981;5070-5075.
4. Huggins C., Hodges C.V. Studies in prostate cancer. I. The effect of castration, of estrogen, and of androgen injection on serum phosphatases in metastatic carcinoma of the prostate. Cancer Res. 1:1941;293-297.
5. Walsh P.C. Physiologic basis for hormonal therapy in carcinoma of the prostate. Urol. Clin. North Am. 2:1975;125-140.
6. Denis L., Murphy G.P. Overview of phase III trials on combined androgen treatment in patients with metastatic prostate cancer. Cancer. 72:1993;3888-3895.
7. Koivisto P., Kolmer M., Visakorpi T., Kallioniemi O.P. Androgen receptor gene and hormonal therapy failure of prostate cancer. Am. J. Pathol. 152:1998;1-9.
8. Chang C.S., Kokontis J., Liao S.T. Molecular cloning of human and rat complementary DNA encoding androgen receptors. Science. 240:1988;324-326.
9. Chang C., Saltzman A., Yeh S., Young W., Keller E., Lee H.J., Wang C., Mizokami A. Androgen receptor: an overview. Crit. Rev. Eukaryot. Gene Expr. 5:1995;97-125.
10. Culig Z., Hobisch A., Cronauer M.V., Radmayr C., Trapman J., Hittmair A., Bartsch G., Klocker H. Androgen receptor activation in prostatic tumor cell lines by insulin-like growth factor-I, keratinocyte growth factor, and epidermal growth factor. Cancer Res. 54:1994;5474-5478.
11. Hobisch A., Eder I.E., Putz T., Horninger W., Bartsch G., Klocker H., Culig Z. Interleukin-6 regulates prostate-specific protein expression in prostate carcinoma cells by activation of the androgen receptor. Cancer Res. 58:1998;4640-4645.
12. Kuil C.W., Berrevoets C.A., Mulder E. Ligand-induced conformational alterations of the androgen receptor analyzed by limited trypsinization. Studies on the mechanism of antiandrogen action. J. Biol. Chem. 270:1995;27569-27576.
13. Rennie P.S., Bruchovsky N., Coldman A.J. Loss of androgen dependence is associated with an increase in tumorigenic stem cells and resistance to cell-death genes. J. Steroid Biochem. Mol. Biol. 37:1990;843-847.
14. Linja M.J., Savinainen K.J., Saramaki O.R., Tammela T.L., Vessella R.L., Visakorpi T. Amplification and overexpression of androgen receptor gene in hormone-refractory prostate cancer. Cancer Res. 61:2001;3550-3555.
15. Tso C.L., McBride W.H., Sun J., Patel B., Tsui K.H., Paik S.H., Gitlitz B., Caliliw R., van Ophoven A., Wu L., deKernion J., Belldegrun A. Androgen deprivation induces selective outgrowth of aggressive hormone-refractory prostate cancer clones expressing distinct cellular and molecular properties not present in parental androgen-dependent cancer cells. Cancer J. 6:2000;220-233.
16. Haldar S., Chintapalli J., Croce C.M. Taxol induces bcl-2 phosphorylation and death of prostate cancer cells. Cancer Res. 56:1996;1253-1255.
17. Fisher D.E. Apoptosis in cancer therapy: crossing the threshold. Cell. 73:1994;539-542.
18. Friesen C., Herr L., Krammer P.H., Debatin K.M. Involvement of the CD95 (APO-1/FAS) receptor/ligand system in drug-induced apoptosis in leukemia cells. Nature Med. 2:1996;574-577.
19. Fluda S., Susin S.A., Kroemer G., Debatin K.M. Molecular ordering of apoptosis induced by anticancer drugs in neuroblastoma cells. Cancer Res. 58:1998;4453-4460.
20. Held K.D. Radiation-induced apoptosis and its relationship to loss of clonogenic survival. Apoptosis. 2:1997;265-282.
21. Denmeade S.R., Lin X.S., Isaacs J.T. Role of programmed (apoptotic) cell death during the progression and therapy for prostate cancer. Prostate. 28:1996;251-265.
22. Radford I.R. Evidence for a general relationship between the induced level of DNA double-strand breakage and cell-killing after X-irradiation of mammalian cells. Int. J. Rad. Biol. Relat. Stud. Phys. Chem. Med. 49:1986;611-620.
23. Ward J.F. DNA damage produced by ionizing radiation in mammalian cells: identities, mechanisms of formation, and reparability. Prog. Nucleic Acid Mol. Biol. 35:1988;95-125.
24. Woods C.M., Zhu J., McQueney P.A., Bollag D., Lazarides E. Taxol-induced mitotic block triggers rapid onset of a p53-independent apoptotic pathway. Mol. Med. 1:1995;506-526.
25. Wahl A.F., Donaldson K.L., Fairchild C., Lee F.Y., Foster S.A., Demers G.W., Galloway D.A. Loss of normal p53 function confers sensitization to Taxol by increasing G2/M arrest and apoptosis. Nature Med. 2:1996;72-79.
26. Danesi R., Figg W.D., Reed E., Myers C.E. Paclitaxel (taxol) inhibits protein isoprenylation and induces apoptosis in PC-3 human prostate cancer cells. Mol. Pharmacol. 47:1995;1106-1111.
27. Li W.X., Franklin W.A. Radiation- and heat-induced apoptosis in PC-3 prostate cancer cells. Radiat. Res. 150:1988;190-194.
28. Wen Y., Hu M.C.T., Makino K., Spohn B., Bartholomeusz G., Yan D.H., Hung M.C. HER-2/neu promotes androgen-independent survival and growth of prostate cancer cells through the Akt pathway. Cancer Res. 60:2000;6841-6845.
29. Cinar B., Koeneman K.S., Edlund M., Prins G.S., Zhau H.E., Chung L.W. Androgen receptor mediates the reduced tumor growth, enhanced androgen responsiveness, and selected target gene transactivation in a human prostate cancer cell line. Cancer Res. 61:2001;7310-7317.
30. Abdel-Mageed A.B., Agrawal K.C. Activation of NF-kappa B: potential role in metallothionein-mediated mitogenic response. Cancer Res. 58:1998;2335-2338.
31. Gogu S.R., Agrawal K.C. The protective role of zinc and N-acetylcysteine in modulating zidovudine induced hematopoietic toxicity. Life Sci. 59:1996;1323-1329.
32. Abdel-Mageed A.B., Agrawal K.C. Antisense down-regulation of metallothionein induces growth arrest and apoptosis in human breast carcinoma cells. Cancer Gene Ther. 4:1997;199-207.
33. Chalepakis G., Postma J.P., Beato M.A. A model for hormone receptor binding to the mouse mammary tumour virus regulatory element based on hydroxyl radical footprinting. Nucleic Acids Res. 16:1988;10237-10247.
34. Tilley W.D., Bentel J.M., Aspinall J.O., Hall R.E., Horsfall D.J. Evidence for a novel mechanism of androgen resistance in the human prostate cancer cell line, PC-3. Steroids. 60:1995;180-186.
35. Tilley W.D., Wilson C.M., Marcelli M., McPhaul M.J. Androgen receptor gene expression in human prostate carcinoma cell lines. Cancer Res. 50:1990;5382-5386.
36. Heisler L.E., Evangelou A., Lew A.M., Trachtenberg J., Elsholtz H.P., Brown T.J. Androgen-dependent cell cycle arrest and apoptotic death in PC-3 prostatic cell cultures expressing a full-length human androgen receptor. Mol. Cell. Endocrinol. 126:1997;59-73.
37. Rehemtulla A., Hamilton A.C., Taneja N., Fridman J., Juan T.S., Maybaum J., Chinnaiyan A. A caspase-resistant form of Bcl-X(L), but not wild type Bcl-X(L), promotes clonogenic survival after ionizing radiation. Neoplasia. 1:1999;63-70.
38. Ofir R., Seidman R., Rabinski T., Krup M., Yavelsky V., Weinstein Y., Wolfson M. Taxol-induced apoptosis in human SKOV3 ovarian and MCF7 breast carcinoma cells is caspase-3 and caspase-9 independent. Cell Death Differ. 9:2002;636-642.
39. Sadi M.V., Barrack E.R. Determination of growth fraction in advanced prostate cancer by Ki-67 immunostaining and its relationship to the time to tumor progression after hormonal therapy. Cancer. 67:1991;3065-3071.
40. Hobisch A., Culig Z., Radmayr C., Bartsch G., Klocker H., Hittmair A. Distant metastases from prostatic carcinoma express androgen receptor protein. Cancer Res. 55:1995;3068-3072.
41. Koivisto P., Kononen J., Palmberg C., Tammela T., Hyytinen E., Isola J., Trapman J., Cleutjens K., Noordzij A., Visakorpi T., Kallioniemi O.P. Androgen receptor gene amplification: a possible molecular mechanism for androgen deprivation therapy failure in prostate cancer. Cancer Res. 57:1997;314-319.
42. Finco T.S., Westwick J.K., Norris J.L., Beg A.A., Der C.J., Baldwin A.S. Jr. Oncogenic Ha-Ras-induced signaling activates NF-kappaB transcriptional activity, which is required for cellular transformation. J. Biol. Chem. 272:1997;24113-24116.
43. Mayo M.W., Baldwin A.S. The transcription factor NF-kappaB: control of oncogenesis and cancer therapy resistance. Biochim. Biophys. Acta. 1470:2000;M55-M62.
44. Preston G.A., Lang J.E., Maronpot R.R., Barrett J.C. Regulation of apoptosis by low serum in cells of different stages of neoplastic progression: enhanced susceptibility after loss of a senescence gene and decreased susceptibility after loss of a tumor suppressor gene. Cancer Res. 54:1994;4214-4223.
45. Olsen N.J., Viselli S.M., Fan J., Kovacs W.J. Androgens accelerate thymocyte apoptosis. Endocrinology. 139:1998;748-752.
46. Zhao X.Y., Ly L.H., Peehl D.M., Feldman D. Induction of androgen receptor by 1alpha,25-dihydroxyvitamin D3 and 9-cis retinoic acid in LNCaP human prostate cancer cells. Endocrinology. 140:1999;1205-1212.
47. Yagoda A., Petrylak D. Cytotoxic chemotherapy for advanced hormone-resistant prostate cancer. Cancer. 71:1993;1098-1109.
48. Eisenberger M.A., Bezerdjian L., Kalash S. A critical assessment of the role of chemotherapy for endocrine-resistant prostatic carcinoma. Urol. Clin. North Amer. 14:1987;695-706.
49. Hudes G.R., Nathan F., Khater C., Haas N., Cornfield M., Giantonio B., Greenberg R., Gomella L., Litwin S., Ross E., Roethke S., McAleer C. Phase II trial of 96-hour paclitaxel plus oral estramustine phosphate in metastatic hormone-refractory prostate cancer. J. Clin. Oncol. 15:1997;3156-3163.
50. Petrylak D.P., Macarthur R.B., O'Connor J., Shelton G., Judge T., Balog J., Pfaff C., Bagiella E., Heitjan D., Fine R., Zuech N., Sawczuk I., Benson M., Olsson C.A. Phase I trial of docetaxel with estramustine in androgen-independent prostate cancer. J. Clin. Oncol. 17:1999;958-967.
51. Smith D.C., Esper P., Strawderman M., Redman B., Pienta K.J. Phase II trial of oral estramustine, oral etoposide, and intravenous paclitaxel in hormone-refractory prostate cancer. J. Clin. Oncol. 17:1999;1664-1671.